Liquidia (LQDA) said Friday the US Food and Drug Administration accepted its resubmitted new drug application for Yutrepia inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
The company said the FDA classified the resubmission as a complete, Class 1 response to an August 2024 action letter that granted tentative approval of Yutrepia, or treprostinil.
The agency set a May 24 target action date, Liquidia said.
Shares of the company were up 1.5% in recent trading Friday.
Price: 15.47, Change: +0.23, Percent Change: +1.48
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。